Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases (Q43860568)
Jump to navigation
Jump to search
scientific article published in January 2002
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases |
scientific article published in January 2002 |
Statements
1 reference
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases (English)
1 reference
Kai U Chow
1 reference
Wolf Daniel Sommerlad
1 reference
Simone Boehrer
1 reference
Bernd Schneider
1 reference
Gernot Seipelt
1 reference
Mathias Johannes Rummel
1 reference
Dieter Hoelzer
1 reference
Paris S Mitrou
1 reference
Eckart Weidmann
1 reference
1 January 2002
1 reference
1 reference
87
1 reference
1
1 reference
33-43
1 reference
Identifiers
1 reference